Return to homepagePandemic Pact

NAT_DHX9: New therapeutic approach against SARS CoV-2 targeting an essential cofactor, RNA helicase DHX9.

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    ANR

  • Principal Investigator

    Jean-Marie Peloponese

  • Research Location

    France

  • Lead Research Institution

    CNRS Montpellier

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The NAT_DHX9 project, coordinated by Jean-Marie Peloponese (UMR (9004) - Institut de Recherche en Infectiologie de Montpellier (IRIM) - CNRS Montpellier), aims to study small molecules with antiviral efficacy capable of binding to the RNA Helicase domain of DHX9 and inhibit its activity. The project aims in particular to characterize the molecular basis of DHX9 interactions with the viral proteins of SARS-CoV-2 to improve the efficiency of molecules, to improve their hepatic stability and to measure their spectrum of antiviral activity in order to propose a new anti-SARS-CoV-2 treatment.